The Full Wiki

More info on 2,5-dimethoxy-4-iodoamphetamine

2,5-dimethoxy-4-iodoamphetamine: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

(Redirected to 2,5-Dimethoxy-4-iodoamphetamine article)

From Wikipedia, the free encyclopedia

DOI
Chemical structure of (R)-DOI
ball-and-stick model of (R)-DOI
IUPAC name
Identifiers
CAS number 64584-34-5,(R): 82864-06-0
(S): 99665-04-0
HCl: 82864-02-6
SMILES
Properties
Molecular formula C11H16INO2
Molar mass 321.15 g/mol
Melting point

201 °C (hydrochloride)

Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

2,5-dimethoxy-4-iodoamphetamine (DOI) is a psychedelic drug and a substituted amphetamine of the phenethylamine family. Despite being a substituted amphetamine it is not a stimulant. DOI has a stereocenter and R-(-)-DOI is the more active stereoisomer. In neuroscience research, [125I]-R-(-)-DOI is used as a radioligand and indicator of the presence of 5-HT2A serotonin receptors. When ingested recreationally, DOI is active at a dosage of 1.5 - 3.0mg (orally) and has a duration of 16 - 30 hours (approximately twice as long as LSD). DOI's effects have been compared to LSD, although there are differences that experienced users can distinguish. Besides the longer duration, the trip tends to be more energetic than an LSD trip, with more body load and a different subjective visual experience. The after effects include residual stimulation and difficulty sleeping, which, depending on the dose, may persist for days.[1] It is often sold as a substitute for LSD, or even sold falsely as LSD[2], which may be dangerous because DOI does not have the same established safety profile as LSD. Unlike LSD, the psychedelic amphetamines (including DOI) can have harmful and potentially fatal physical effects in overdose. Although there have been no known deaths due to DOI ingestion, it is relatively new on the recreational scene so long-term effects are not known.

Contents

Pharmacology

DOI is a selective 5-HT2A, 5-HT2B, and 5-HT2C receptor partial agonist. Its psychedelic effects are mediated by its agonistic properties at the 5-HT2A receptor. Due to its selectivity, DOI is often used in scientific research when studying the 5-HT2 receptor subfamily.

The solubility of DOI hydrochloride in H2O is 10 mg/ml, and in ethanol 2 mg/ml [3].

DOI has also recently been shown to be an extremely potent inhibitor of Tumor necrosis factor-alpha, an inflammatory mediator which is an important target for current research into degenerative conditions such as arthritis and Alzheimer's disease, where the disease process involves tissue damage through chronic inflammation. This could make DOI and other 5-HT2A agonists an entirely new area for development of novel treatments for these conditions.[4]

History

DOI was first synthesized by Alexander Shulgin. The radioactive iodine-125 form of DOI was first developed in the lab of David E. Nichols. In January 2007, British Police reported that 3 young men had taken ill, reportedly, after taking DOI at a rave in Biggleswade, near Milton Keynes, and warned others who had taken it to seek medical attention. This would appear to be the first indication that DOI has found more widespread use as a recreational drug in the UK. [5]

See also

References

  1. ^ Shulgin, Alexander; Ann Shulgin (1991). PiHKAL- Phenethylamines i Have Known And Loved: A Chemical Love Story. Transform Press. ISBN 0-9630096-0-5. http://www.erowid.org/library/books_online/pihkal/pihkal067.shtml. Retrieved 2/12/09.  
  2. ^ DEA Mircrogram. DEA, United States Government. June 2008. http://www.usdoj.gov/dea/programs/forensicsci/microgram/mg0608/mg0608.html. Retrieved 2/12/09.  
  3. ^ "D101 DOI hydrochloride ≥98% (HPLC), solid". http://www.sigmaaldrich.com/catalog/search/ProductDetail/SIGMA/D101.  
  4. ^ Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, Nichols CD. Serotonin 5-Hydroxytryptamine2A Receptor Activation Suppresses Tumor Necrosis Factor-α-Induced Inflammation with Extraordinary Potency. Journal of Pharmacology And Experimental Therapeutics. 2008;327:316-323. doi:10.1124/jpet.108.143461
  5. ^ BBC, "New drug alert as three taken ill", BBC News, 29 January 2007.

External links








Got something to say? Make a comment.
Your name
Your email address
Message